J Cancer Prev 2023; 28(1): 24-28
Published online March 30, 2023
https://doi.org/10.15430/JCP.2023.28.1.24
© Korean Society of Cancer Prevention
Mark Steven Miller *, Altaf Mohammed *
Division of Cancer Prevention, National Cancer Institute, Rockville, MD, USA
Correspondence to :
Mark Steven Miller, E-mail: mark.miller5@nih.gov, https://orcid.org/0000-0003-1191-0977
Altaf Mohammed, E-mail: altaf.mohammed@nih.gov, https://orcid.org/0000-0003-1058-6909
*These authors contributed equally to this work as co-correspondence authors.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Advances in omics and immunology over the past 20 years have revolutionized the approach to cancer prevention, with the goal now focused on identifying populations at higher risk for developing cancer in their lifetime as a result of either extensive exposure to environmental carcinogens or harboring precancer lesions or inherited genetic mutations that predispose them to specific types of cancer(s). Thus, the naïve idea that cancer could be “prevented” in the general population has evolved to a more practical approach based on the understanding that the target population for preventive agents will be individuals who already have alterations, in gene pathways, whether inherited or environmentally caused, and the goal will be to “intercept” these lesions at the earliest stages in the path from an initial genetic lesion to full-blown cancer. The Division of Cancer Prevention of the National Cancer Institute and the Office of Disease Prevention at the National Institutes of Health recently sponsored the second biennial “Translational Advances in Cancer Preventive Agent Development Meeting,” held virtually from September 7–9th. In this Meeting Report, we highlight the scientific sessions of this meeting that covered the most recent advances in preventive agent development that also highlighted these rapidly emerging trends in this research area.
Keywords: Chemoprevention, Immunoprevention, Interception, Prevention
Altaf Mohammed, Roderick H. Dashwood, Sally Dickinson, Mary L. Disis, Elizabeth M. Jaffee, Bryon D. Johnson, Samir N. Khleif, Michael N. Pollak, Jeffrey Schlom, Robert H. Shoemaker, Sasha E. Stanton, Georg T. Wondrak, Ming You, Hao Zhu, Mark Steven Miller
J Cancer Prev 2021; 26(4): 309-317 https://doi.org/10.15430/JCP.2021.26.4.309Mark Steven Miller, Peter J. Allen, Powel H. Brown, Andrew T. Chan, Margie L. Clapper, Roderick H. Dashwood, Shadmehr Demehri, Mary L. Disis, Raymond N. DuBois, Robert J. Glynn, Thomas W. Kensler, Seema A. Khan, Bryon D. Johnson, Karen T. Liby, Steven M. Lipkin, Susan R. Mallery, Emmanuelle J. Meuillet, Richard B.S. Roden, Robert E. Schoen, Zelton D. Sharp, Haval Shirwan, Jill M. Siegfried, Chinthalapally V. Rao, Ming You, Eduardo Vilar, Eva Szabo, Altaf Mohammed
J Cancer Prev 2021; 26(1): 71-82 https://doi.org/10.15430/JCP.2021.26.1.71Kyle J. Gu, Guojun Li
J Cancer Prev 2020; 25(3): 127-135 https://doi.org/10.15430/JCP.2020.25.3.127